908 Devices, Inc. (MASS)
| Market Cap | 1.01B |
| Revenue (ttm) | 25.59M |
| Net Income (ttm) | n/a |
| Shares Out | 27.65M |
| EPS (ttm) | -1.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 221,155 |
| Open | 38.00 |
| Previous Close | 38.20 |
| Day's Range | 36.24 - 38.20 |
| 52-Week Range | 29.20 - 79.60 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 55.00 (+51.2%) |
| Est. Earnings Date | Nov 3, 2021 |
About MASS
908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a smal...
Financial Performance
In 2020, 908 Devices's revenue was $26.89 million, an increase of 49.64% compared to the previous year's $17.97 million. Losses were -$12.82 million, -4.14% less than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for 908 Devices stock is "Strong Buy." The 12-month stock price forecast is 55.00, which is an increase of 51.18% from the latest price.
News
908 Devices Shares Gain On Handheld, Desktop Devices Led Q2 Revenue Beat, FY21 Guidance Above Consensus
908 Devices Inc (NASDAQ: MASS) reported a second-quarter FY21 revenue decline of 26% year-on-year to $8.3 million, beating the analyst consensus of $7.2 million. The revenue grew 49% Q/Q.
908 Devices Reports Second Quarter 2021 Financial Results and Raises 2021 Revenue Outlook
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for t...
908 Devices Expands Scientific Advisory Board, Creates Dedicated Proteomics Panel
BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment...
908 Devices Expands Strategic Distribution Network in APAC, Europe, and the Americas
BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the expansion of its channel...
908 Devices and Transcenta's Joint Innovation Partnership Accelerates Biopharma Development
BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced outcomes of its joint innova...
908 Devices Announces New Data Integrations with Key Industry Partners to Accelerate BioProcess Data Insights
BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced two data analysis partnershi...
908 Devices Appoints Marcia Eisenberg, Ph.D., Chief Scientific Officer of Labcorp Diagnostics, to its Board of Directors
BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS), a pioneer of purpose-built, handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Marcia Eisenberg, Ph...
908 Devices Reports First Quarter 2021 Financial Results and Reiterates 2021 Revenue Outlook
Q1 2021 Product and Service Revenue Increased More Than 100% Over Prior Year Q1 2021 Product and Service Revenue Increased More Than 100% Over Prior Year
908 Devices Launches New Aerosol Module for Handheld MX908
BOSTON--(BUSINESS WIRE)--New Features Enable Detection of Aerosols and New Synthetic Drug Targets; Remote Bluetooth App Enables Rapid Data Sharing
908 Devices Increases Focus on Biotherapeutics with Expansion of Scientific Advisory Board
BOSTON--(BUSINESS WIRE)--908 Devices Appoints Six New Members to its Scientific Advisory Board
908 Devices and Bio-Techne Announce Joint Collaboration
BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) today announced a joint collaboration to develop an extended workflow solution for protein cha...
Bio-Techne and 908 Devices Announce Joint Collaboration
MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution fo...
908 Devices to Report First Quarter Financial Results on May 13, 2021 and Host 2021 Annual Meeting of Stockholders on...
BOSTON, April 14, 2021 (GLOBE NEWSWIRE) -- 908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it w...
908 Devices Appoints Michele Fournier as Chief People Officer
BOSTON--(BUSINESS WIRE)--Experienced HR executive with global tech background joins executive leadership team
908 Devices Provides Handheld Mass Spec for Trace Detection to U.S. Border Patrol
BOSTON--(BUSINESS WIRE)--Agency selected the MX908 to work closely with local law enforcement to prevent drug smuggling as opioid crisis rages across the country.
908 Devices Reports 50% Top Line Growth, Guides 2021 Up 45%
908 Devices expects 45% revenue growth this year. About 8% below its IPO price, MASS could be a good bet.
Cathie Wood Is Bullish On 908 Devices. An Analyst Makes A Case For The Stock
908 Devices Inc (NASDAQ: MASS) is seen as a high-growth life science tools company that analysts at SVB Leerink expect to “outperform” despite conservative 2021 guidance given by its management due to t...
908 Devices Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Revenue Outlook
2020 Revenue Increased 50% Over Prior Year 2020 Revenue Increased 50% Over Prior Year
908 Devices Awarded Multi-Year $25M Purchase Order to Enable the U.S. Army
Multi-mission device will support field teams with trace detection point of need analysis Multi-mission device will support field teams with trace detection point of need analysis
5 Recent Red-Hot IPOs Are Being Added to the Russell 2000 Next Week
Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.
908 Devices Appoints Jeff George and Fenel Eloi to its Board of Directors
BOSTON--(BUSINESS WIRE)--Company adds two directors with financial, pharmaceutical, and consumable business expertise.
908 Devices to Report Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021
BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financi...
908 Devices to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will participate in...
908 Devices Strengthens Commercial Team with Addition of New Vice President
BOSTON--(BUSINESS WIRE)--Bioprocess Veteran Steve Davenport joins company as Vice President of Commercial Sales.